Citation： Chinese Society of Reproductive Medicine (CSRM). Chinese practice guideline on the assisted reproductive technology (ART) strategies for women with advanced age. Chinese Journal of Evidence-Based Medicine, 2019, 19(3): 253-270. doi: 10.7507/1672-2531.201812103 Copy
| 1. | Bushnick T, Garner R. The children of older first-time mothers in Canada: their health and development. Ottawa (ON): Statistics Canada. Available at: http://www.statcan.gc.ca/pub/89-599-m/89-599-m2008005-eng.htm. |
| 2. | National Center for Health Statistics Data Brief No. 232. Mean age of mothers is on the rise: United States, 2000-2014. Available at: http://www.cdc.gov/nchs/data/databriefs/db232.pdf. |
| 3. | Royal college of obstetricians and gynaecologists. RCOG statement on later maternal age. Available at: http://www.rcog.org.uk/what-we-do/campaigning-and-opinions. |
| 4. | 李月花, 王艳萍, 代礼, 等. 基于医院的全国高龄产妇比率变化趋势. 中华预防医学杂志, 2009, 43(12): 1073-1076. |
| 5. | 孟茜, 林鹏. 二胎政策开放与未开放高危妊娠妇女分布人群差异性调查. 中国妇幼保健, 2016, 31(20): 4266-4268. |
| 6. | Johnson JA, Tough S, SOGC Genetics Committee. Delayed child-bearing. J Obstet Gynaecol Can, 2012, 34(1): 80-93. |
| 7. | 谢幸, 苟文丽. 妇产科学(第八版). 北京: 人民卫生出版社, 2013: 372. |
| 8. | Barkan SE, Bracken MB. Delayed childbearing: no evidence for increased risk of low birth weight and preterm delivery. Am J Epidemiol, 1987, 125(1): 101-109. |
| 9. | 张惠粉. 高龄产妇分娩的危险因素分析. 中国现代药物应用, 2014, 35(9): 51-52. |
| 10. | Khalil A, Syngelaki A, Maiz N, et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol, 2013, 42(6): 634-643. |
| 11. | Usta IM, Nassar AH. Advanced maternal age. Part I: obstetric complications. Am J Perinatol, 2008, 25(8): 521-534. |
| 12. | 胡琳莉, 黄国宁, 孙海翔, 等. 多胎妊娠减胎术操作规范 (2016). 生殖医学杂志, 2017, 26(3): 193-198. |
| 13. | 胡琳莉, 黄国宁, 孙海翔, 等. 促排卵药物使用规范 (2016). 生殖医学杂志, 2017, 26(4): 302-307. |
| 14. | Penzias A, Bendikson K, Butts S, et al. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril, 2017, 107(4): 901-903. |
| 15. | Okun N, Sierra S, Committee G, et al. Pregnancy outcomes after assisted human reproduction. J Obstet Gynaecol Can, 2014, 36(1): 64. |
| 16. | National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London: Royal College of Obstetricians & Gynaecologists, 2013. |
| 17. | Myers ER, Mccrory DC, Mills AA, et al. Effectiveness of assisted reproductive technology (ART). Evid Rep Technol Assess (Full Rep), 2008, (167): 1-195. |
| 18. | Organization WH. WHO Handbook for Guideline Development. Second edition. 2014. |
| 19. | 蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序. 中华医学杂志, 2016, 96(4): 205-253. |
| 20. | 胡琳莉, 黄国宁, 孙海翔, 等. CSRM 指南共识的制定规范 (2016). 生殖医学杂志, 2017, 26(4): 289-301. |
| 21. | Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ, 2010, 182(18): 1308-1311. |
| 22. | 韦当, 王聪尧, 肖晓娟, 等. 指南研究与评价 (AGREEⅡ) 工具实例解读. 中国循证儿科杂志, 2013, 8(4): 316-319. |
| 23. | Chen Y, Yang K, Marušic A, et al. A Reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132. |
| 24. | International practice guideline registry platform. Available at: http://www.guidelines-registry.org. |
| 25. | Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7(2): 1-7. |
| 26. | Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 2011, 343(2): d5928. |
| 27. | Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536. |
| 28. | Wells GA, Shea BJ, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric, 2014, 18(6): 727-734. |
| 29. | Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 2011, 64(4): 383-394. |
| 30. | 陈耀龙, 姚亮, Norris SL, 等. GRADE 在系统评价中应用的必要性及注意事项. 中国循证医学杂志, 2013, 13(12): 1401-1404. |
| 31. | Vernooij RWM, Alonsocoello P, Brouwers M, et al. Reporting Items for updated clinical guidelines: checklist for the reporting of updated guidelines (CheckUp). PLoS Med, 2017, 14(1): e1002207. |
| 32. | Hamilton BE, Martin JA, Osterman MJ, et al. Births: final data for 2014. Natl Vital Stat Rep, 2015, 64: 1. |
| 33. | 张亚峰, 孙桂香. 低体重儿母亲妊娠期危险因素的 Meta 分析. 中国妇幼保健, 2016, 31(5): 1115-1118. |
| 34. | Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet, 2011, 377(9774): 1331-1340. |
| 35. | Morris JK, Vigan CD, Mutton DE, et al. Risk of a Down syndrome live birth in women 45 years of age and older. Prenat Diagn, 2005, 25(4): 275-278. |
| 36. | Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled Studies. BMJ, 2005, 330(7491): 565. |
| 37. | Heffner LJ. Advanced maternal age--how old is too old? N Engl J Med, 2004, 351(19): 1927-1929. |
| 38. | 薛静, 陈立章, 薛蕾, 等. 小儿脑性瘫痪母亲妊娠期危险因素的 Meta 分析. 中国当代儿科杂志, 2013, 15(7): 535-540. |
| 39. | 孙瑜, 朱依敏. 高龄不育夫妇: 现在辅助生殖技术之惑. 中国计划生育和妇产科, 2014, 6(8): 1-3. |
| 40. | 杨燕飞, 傅锦媚, 阮祥燕. 子宫肌瘤患病年龄分布与追踪研究. 实用妇产科杂志, 2008, 24(5): 299-301. |
| 41. | 乔杰, 杨蕊. 高龄辅助生殖技术临床结局. 中国实用妇科与产科杂志, 2017, 33(1): 64-67. |
| 42. | Timofeev J, Reddy UM, Huang CC, et al. Obstetric complications, neonatal morbidity, and indications for cesarean delivery by maternal age. Obstet Gynecol, 2013, 122(6): 1184-1195. |
| 43. | Pregnancy in older age increases stroke, heart attack risk years later.AHA/ASA Newsroom. 2016. Available at: http://newsroom.heart.org/news/pregnancy-in-older-age-increases-stroke-heart-attack-risk-years-later. |
| 44. | Committee Opinion No. 589: Female age-related fertility decline. Obstet Gynecol, 2014: 663-634. |
| 45. | O’Flynn N. Fertility: assessment and treatment for people with fertility problems: NICE guideline. Br J Gen Pract, 2014, 64(618): 50-51. |
| 46. | Reproductive Endocrinology and Infertility Committee. Advanced reproductive age and fertility. J Obstet Gynaecol Can, 2011, 33(11): 1165-1175. |
| 47. | 中国医师协会生殖医学专业委员会. 高龄女性不孕诊治指南. 生殖与避孕, 2017, 37(2): 87-100. |
| 48. | Faddy MJ, Gosden RG, Gougeon A. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod, 1992, 7(10): 1342-1346. |
| 49. | 刘继龙, 林春莲, 蒙钟明, 等. 年龄及性激素预测卵巢储备功能的临床研究. 基层医学论坛, 2013, 17(1): 3-4. |
| 50. | 2015 assisted reproductive technology fertility clinic success rates report, national center for chronic disease prevention and health promotion & division of reproductive health. Available at: https://www.cdc.gov/art/reports/2015/fertility-clinic.html. |
| 51. | 梁琳, 陈秀娟. 高龄不孕患者不同辅助生殖技术的胚胎发育情况及妊娠结局分析. 中华妇幼临床医学杂志 (电子版), 2014, 10(6): 770-773. |
| 52. | 谢雅琴, 肖红, 柳鸣, 等. 行辅助生殖技术治疗的高龄不孕女性生育二胎的心理健康相关因素分析. 生殖与避孕, 2016, 36(12): 1031-1035. |
| 53. | Kelly-Weeder S, Cox CL. The Impact of lifestyle risk factors on female infertility. Women Health, 2006, 44(4): 1-23. |
| 54. | 韩晓霞, 左瑞菊, 马肖. 窦卵泡计数、抗苗勒管激素与性激素检测评价卵巢储备的研究. 中国医药导报, 2017, 14(18): 117-120. |
| 55. | 陈士岭. 卵巢储备功能的评价. 国际生殖健康/计划生育杂志, 2009, 28(5): 281-286. |
| 56. | Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril, 2015, 103(03): e9-e17. |
| 57. | Zhang HH, Xu PY, Wu J, et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J Ovarian Res, 2014, 7(1): 93. |
| 58. | 宋慧玲, 郭艺红, 孙莹璞, 等. 生长激素对不同年龄卵巢储备功能趋于低下患者 IVF-ET 治疗结局的影响. 生殖与避孕, 2013, 33(1): 58-62. |
| 59. | Kara M, Aydin T, Aran T, et al. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur J Obstet Gynecol Reprod Biol, 2014, 173: 63-65. |
| 60. | Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet, 2007, 24(12): 629-634. |
| 61. | Smotrich DB, Widra EA, Gindoff PR, et al. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril, 1995, 64(6): 1136. |
| 62. | Broer SL, Broekmans FJ, Laven JS, et al. Anti-mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update, 2014, 20(5): 688-701. |
| 63. | Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology, 2002, 143(3): 1076-1084. |
| 64. | Wang LR, Wang Y, Lou Y, et al. Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril, 2015, 103(1): 119. |
| 65. | 杨泽星, 朱琼媛, 赵富鲜, 等. 早卵泡期血清抗苗勒管激素水平在预测卵巢低反应中的价值探讨. 实用妇产科杂志, 2016, 32(8): 32. |
| 66. | Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertil Steril, 2013, 99(7): 1825. |
| 67. | Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA, 2017, 318(14): 1367-1376. |
| 68. | Eldar-Geva T, Ben-Chetrit A, Spitz IM, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod, 2005, 20(11): 3178-3183. |
| 69. | McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod, 2007, 22(3): 778-785. |
| 70. | Hall JE, Welt CK, Cramer DW. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum Reprod, 1999, 14(2): 409-415. |
| 71. | Creus M, Penarrubia J, Fabregues F, et al. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod, 2000, 15(11): 2341-2346. |
| 72. | Smeenk JM, Sweep FC, Zielhuis GA, et al. Anti-mullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril, 2007, 87(1): 223-226. |
| 73. | Practice COG. Committee opinion no. 618: Ovarian reserve testing. Obstet Gynecol, 2015, 125(1): 268. |
| 74. | Kwe J, Ehing ME, Sehats R, et al. Ovarian volume and antral follicle count for the prediction of low an d hyper responders with in vitro fertilization. Reprod Biol Endco rinol, 2007, 15(5): 9-18. |
| 75. | Frattarelli JL, Lauria-Costab DF, Miller BT, et al. Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. Fertil Steril, 2000, 74(3): 512-517. |
| 76. | Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. J Gynecol Obstet Hum Reprod, 2017, 46(1): 1-7. |
| 77. | Ji J, Ju XQ, Wang JF, et al. Effectiveness of dehydroepiandrosterone in poor ovarian responders undergoing in vitro fertilization: a meta-analysis of randomized controlled trials. Int J Clin Exp Med, 2016, 9(11): 20835-20845. |
| 78. | Li J, Yuan H, Chen Y, et al. A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. Int J Gynaecol Obstet, 2015, 131(3): 240-245. |
| 79. | 董娟, 徐望明, 董兰, 等. IVF-ET 前使用脱氢表雄酮对卵巢储备功能低下患者妊娠结局影响的系统评估. 生殖医学杂志, 2015, 24(6): 436-443. |
| 80. | Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med, 2009, 6(9): 2579-2590. |
| 81. | Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst, 2005, 97(10): 755-765. |
| 82. | Li XL, Wang L, Lv F, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore), 2017, 96(12): e6443. |
| 83. | Harper K, Proctor M, Hughes E, et al. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev, 2009, (3): CD000099. |
| 84. | 张平, 王蕴颖. 生长激素辅助促排卵改善卵巢低反应患者不孕治疗的结局. 中国妇幼保健, 2012, 27(3): 395-396. |
| 85. | 孙婧, 权孝珍, 谢明霞, 等. 1382 周期宫腔内夫精人工授精临床因素分析. 中国妇幼保健, 2011, 26(11): 1658-1660. |
| 86. | 陈辉, 周敏, 李秋颖, 等. 影响夫精宫腔内人工授精临床妊娠率的相关因素分析. 中国优生与遗传杂志, 2012, 20(1): 98-101. |
| 87. | 卢伟英, 刘西茹, 黄元华, 等. 718 周期夫精宫腔内人工授精临床因素分析. 海南医学院学报, 2006, 12(4): 310-313. |
| 88. | 程艽, 张莉嘉, 苏慧. 男性不育相关因素对夫精人工授精妊娠率的影响. 中国优生与遗传杂志, 2011, 19(3): 99-102. |
| 89. | Goldman MB, Thornton KL, Ryley D, et al. A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). Fertil Steril, 2014, 101(6): 1574-1581. |
| 90. | Hill MJ, Levens ED, Levy G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril, 2012, 97(5): 1108-1114. |
| 91. | 熊芳, 周萍, 胡玲卿, 等. 重组促黄体生成素在卵巢储备正常患者超促排卵中的作用. 中国妇幼保健, 2016, 31(2): 336-338. |
| 92. | 杨军, 吴淑卿. 长效长方案超促排卵中晚期添加黄体生成素对体外受精-胚胎移植结局的影响. 国际医药卫生导报, 2016, 22(19): 2929-2933. |
| 93. | Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged≥ 35 years: a randomized controlled trial. Hum Reprod, 2015, 30(5): 1188-1195. |
| 94. | Mochtar MH, Veen FVD. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev, 2007, (2): CD005070. |
| 95. | Boulet SL, Mehta A, Kissin DM. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA, 2015, 313(3): 255-263. |
| 96. | Rumste MMV, Evers JL, Farquhar C. Intra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in couples with non-male subfertility. Cochrane Database Syst Rev, 2003, (2): CD001301. |
| 97. | Wen J, Jie J, Ding C, et al. Birth defects in children conceived by invitro fertilization and intracytoplasmic sperm injection: a meta-analysis. Fertil Steril, 2012, 97(6): 1331-1337. |
| 98. | National Institute for Health and Care Excellence. Fertility problems assessment and treatment. 2013. |
| 99. | Abramowicz J S, Kossoff G, Maršál K, et al. International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). Ultrasound Obstet Gynecol, 2000, 16(6): 594-596. |
| 100. | Harton G, Braude P, Lashwood A, et al. ESHRE PGD consortium best practice guidelines for organization of a PGD centre for PGD/preimplantation genetic screening. Hum Reprod, 2010, 26(1): 14-24. |
| 101. | Okun N, Sierra S, Wilson RD, et al. Pregnancy outcomes after assisted human reproduction. J Obstet Gynaecol Can, 2014, 36(1): 64-83. |
| 102. | Staessen C, Platteau P, Van AE, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. Hum Reprod, 2004, 19(12): 2849-2858. |
| 103. | Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med, 2007, 357(17): 1770. |
| 104. | Platteau P, Staessen C, An M, et al. Preimplantation genetic diagnosis for aneuploidy screening in patients with unexplained recurrent miscarriages. Fertil Steril, 2005, 83(2): 393-397. |
| 105. | Blockeel C, Schutyser V, De Vos A, et al. Prospectively randomized controlled trial of PGS in IVF/ICSI patients with poor implantation. Reprod Biomed Online, 2008, 17(6): 848-854. |
| 106. | Mastenbroek S, Twisk M, Van der Veen F, et al. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. Hum Reprod Update, 2011, 19(2): 454-466. |
| 107. | Chen M, Wei S, Hu J, et al. Can comprehensive chromosome screening technology improve IVF/ICSI outcomes? A meta-analysis. PLoS One, 2015, 10(10): e0140779. |
| 108. | Yang Z, Lin J, Zhang J, et al. Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study. BMC Med Genomics, 2015, 8(1): 30. |
| 109. | Lai HH, Chuang TH, Wong LK, et al. Identification of mosaic and segmental aneuploidies by next-generation sequencing in preimplantation genetic screening can improve clinical outcomes compared to array-comparative genomic hybridization. Mol Cytogenet, 2017, 10(1): 14. |
| 110. | 徐艳文, 黄国宁, 孙海翔, 等. 高通量基因测序植入前胚胎遗传学诊断和筛查技术规范 (试行). 生殖医学杂志, 2017, 26(5): 391-398. |
| 111. | 黄锦, 马彩虹. 植入前胚胎遗传学诊断及筛查技术与规范. 中国实用妇科与产科杂志, 2015, 31(9): 814-817. |
| 112. | 孙莹璞, 李刚. PGD/PGS 的安全性. 2014 浙江省计划生育与生殖医学学术年会暨“生殖安全转化医学研讨会”, 2014. |
| 113. | Pandian Z, Marjoribanks J, Ozturk O, et al. Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection. Cochrane Database Syst Rev, 2013, (7): CD003416. |
| 114. | McLernon DJ, Harrild K, Bergh C, et al. Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials. BMJ, 2010, 341: c6945. |
| 115. | Kissin DM, Kulkarni AD, Kushnir VA, et al. Number of embryos transferred after in vitro fertilization and good perinatal outcome. Obstet Gynecol, 2014, 123(2 Pt 1): 239-247. |
| 116. | Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril, 2017, 107(4): 901-903. |
| 117. | NICE. Fertility problems: assessment and treatment (CG156). 2016. Available at: https://www.nice.org.uk/guidance/cg156/resources/. |
| 118. | Lawlor DA, Nelson SM. Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. Lancet, 2012, 379(9815): 521-527. |
| 119. | Fiddelers AA, Severens JL, Dirksen CD, et al. Economic evaluations of single- versus double-embryo transfer in IVF. Hum Reprod Update, 2007, 13(1): 5-13. |
| 120. | Scotland GS, McLernon D, Kurinczuk JJ, et al. Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon. BJOG, 2011, 118(9): 1073-1083. |
| 121. | Kjellberg AT, Carlsson P, Bergh C. Randomized single versus double embryo transfer: obstetric and paediatric outcome and a cost-effectiveness analysis. Hum Reprod, 2006, 21(1): 210-216. |
| 122. | Joint Society of Obstetricians and Gynaecologist of Canada–Canadian Fertility and Andrology Society Clinical Practice Guidelines Committee. Elective Single Embryo Transfer Following in vitro Fertilization. J Obstet Gynaecol Can, 2010, 32(4): 363-377. |
| 123. | Gardner DK, Surrey E, Minjarez D, et al. Single blastocyst transfer: a prospective randomized trial. Fertil Steril, 2004, 81(3): 551-555. |
| 124. | The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology. Criteria for number of embryos to transfer: a committee opinion. Fertil Steril, 2013, 99(1): 44-46. |
| 125. | 薛亚梅, 童晓嵋, 张松英. 黄体酮肌肉注射与阴道缓释凝胶对 IVF-ET 结局影响的 Meta 分析. 生殖与避孕, 2015, 35(4): 252-258. |
| 126. | Zargar M, Saadati N, Ejtahed MS. Comparison the effectiveness of oral dydrogesterone, vaginal progesterone suppository and progesterone ampule for luteal phase support on pregnancy rate during ART cycles. Int J Pharm Res Allied Sci, 2016, 5(3): 229-236. |
| 127. | Saharkhiz N, Zamaniyan M, Salehpour S, et al. A comparative study of dydrogesterone and micronized Progesterone for luteal Phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol, 2016, 32(3): 213-217. |
| 128. | 魏臻, 孙骏. 黄体酮注射液事件引起的安全用药思考. 中国药房, 2016, 27(13): 1749-1751. |
| 129. | 张红英. 黄体酮肌内注射的局部不良反应与护理措施. 中国医药指南, 2012, 10(21): 672-673. |
| 130. | 中华人民共和国卫生部. 人类辅助生殖技术规范. 中国生育健康杂志, 2004, 15(1): 4-9. |
| 131. | Dodd JM, Dowswell T, Crowther CA. Reduction of the number of fetuses for women with a multiple pregnancy. Cochrane Database Syst Rev, 2015, (11): CD003932. |
| 132. | 王蕴颖, 赵静, 张平, 等. 体型瘦小女性经辅助生殖获双胎妊娠后减胎与否对妊娠结局的影响. 中国妇幼保健, 2013, 28(26): 4343-4344. |
| 133. | Gupta S, Fox N S, Feinberg J, et al. Outcomes in twin pregnancies reduced to singleton pregnancies compared with ongoing twin pregnancies. Am J Obstet Gynecol, 2015, 213(4): 580. |
| 134. | 潘云冬. 辅助生殖技术后多胎妊娠减灭术对妊娠结局及子代的影响. 杭州: 浙江大学, 2015. |
| 135. | 赵霞. 123 例多胎妊娠行选择性减胎患者妊娠结局临床因素分析. 武汉: 华中科技大学, 2011. |
| 136. | 刘艳, 王谢桐, 李红燕, 等. 多胎妊娠选择性减胎术的时机对妊娠结局的影响. 中华围产医学杂志, 2012, 15(10): 605-609. |
| 137. | Haas J, Barzilay E, Hourvitz A, et al. Outcome of early versus late multi-fetal pregnancy reduction. Reprod Biomed Online, 2016, 33(5): 629-634. |
| 138. | 朱小凤. 减胎时机与妊娠结局的关系研究. 中国实用医药, 2009, 4(30): 201-202. |
| 139. | Seoud MA, Toner JP, Kruithoff C, et al. Outcome of twin, triplet, and quadruplet in vitro fertilization pregnancies: the Norfolk experience. Fertil Steril, 1992, 57(4): 825. |
| 140. | Stevenson R C, Mccabe C J, Pharoah P O, et al. Cost of care for a geographically determined population of low birthweight infants to age 8-9 years. II. Arch Dis Child Fetal Neonatal Ed, 1996, 74(2): F118. |
| 141. | 刘泽星, 薛薇, 邓燕, 等. 阴道给药与肌内注射黄体酮对子宫内膜孕激素水平影响的研究. 实用妇产科杂志, 2017, 33(3): 220-222. |
| 142. | 赵敏, 郑文捷, 李晓东, 等. 黄体酮注射液与阴道缓释凝胶对实施体外受精与胚胎移植技术孕妇妊娠结局的影响比较: Meta 分析. 福建医科大学学报, 2017, 51(1): 61-67. |
| 143. | 连海丽. 口服地屈孕酮在黄体功能不全所致先兆流产保胎中的优势临床观察. 中国现代药物应用, 2016, 10(16): 219-220. |
| 144. | 胡晓东, 彭月婷, 曾勇, 等. 阴道黄体酮栓剂黄体支持是否更具优点? 生殖医学杂志, 2010, 19(3): 196-199. |
- 1. Bushnick T, Garner R. The children of older first-time mothers in Canada: their health and development. Ottawa (ON): Statistics Canada. Available at: http://www.statcan.gc.ca/pub/89-599-m/89-599-m2008005-eng.htm.
- 2. National Center for Health Statistics Data Brief No. 232. Mean age of mothers is on the rise: United States, 2000-2014. Available at: http://www.cdc.gov/nchs/data/databriefs/db232.pdf.
- 3. Royal college of obstetricians and gynaecologists. RCOG statement on later maternal age. Available at: http://www.rcog.org.uk/what-we-do/campaigning-and-opinions.
- 4. 李月花, 王艳萍, 代礼, 等. 基于医院的全国高龄产妇比率变化趋势. 中华预防医学杂志, 2009, 43(12): 1073-1076.
- 5. 孟茜, 林鹏. 二胎政策开放与未开放高危妊娠妇女分布人群差异性调查. 中国妇幼保健, 2016, 31(20): 4266-4268.
- 6. Johnson JA, Tough S, SOGC Genetics Committee. Delayed child-bearing. J Obstet Gynaecol Can, 2012, 34(1): 80-93.
- 7. 谢幸, 苟文丽. 妇产科学(第八版). 北京: 人民卫生出版社, 2013: 372.
- 8. Barkan SE, Bracken MB. Delayed childbearing: no evidence for increased risk of low birth weight and preterm delivery. Am J Epidemiol, 1987, 125(1): 101-109.
- 9. 张惠粉. 高龄产妇分娩的危险因素分析. 中国现代药物应用, 2014, 35(9): 51-52.
- 10. Khalil A, Syngelaki A, Maiz N, et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol, 2013, 42(6): 634-643.
- 11. Usta IM, Nassar AH. Advanced maternal age. Part I: obstetric complications. Am J Perinatol, 2008, 25(8): 521-534.
- 12. 胡琳莉, 黄国宁, 孙海翔, 等. 多胎妊娠减胎术操作规范 (2016). 生殖医学杂志, 2017, 26(3): 193-198.
- 13. 胡琳莉, 黄国宁, 孙海翔, 等. 促排卵药物使用规范 (2016). 生殖医学杂志, 2017, 26(4): 302-307.
- 14. Penzias A, Bendikson K, Butts S, et al. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril, 2017, 107(4): 901-903.
- 15. Okun N, Sierra S, Committee G, et al. Pregnancy outcomes after assisted human reproduction. J Obstet Gynaecol Can, 2014, 36(1): 64.
- 16. National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London: Royal College of Obstetricians & Gynaecologists, 2013.
- 17. Myers ER, Mccrory DC, Mills AA, et al. Effectiveness of assisted reproductive technology (ART). Evid Rep Technol Assess (Full Rep), 2008, (167): 1-195.
- 18. Organization WH. WHO Handbook for Guideline Development. Second edition. 2014.
- 19. 蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序. 中华医学杂志, 2016, 96(4): 205-253.
- 20. 胡琳莉, 黄国宁, 孙海翔, 等. CSRM 指南共识的制定规范 (2016). 生殖医学杂志, 2017, 26(4): 289-301.
- 21. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ, 2010, 182(18): 1308-1311.
- 22. 韦当, 王聪尧, 肖晓娟, 等. 指南研究与评价 (AGREEⅡ) 工具实例解读. 中国循证儿科杂志, 2013, 8(4): 316-319.
- 23. Chen Y, Yang K, Marušic A, et al. A Reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
- 24. International practice guideline registry platform. Available at: http://www.guidelines-registry.org.
- 25. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7(2): 1-7.
- 26. Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 2011, 343(2): d5928.
- 27. Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536.
- 28. Wells GA, Shea BJ, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric, 2014, 18(6): 727-734.
- 29. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 2011, 64(4): 383-394.
- 30. 陈耀龙, 姚亮, Norris SL, 等. GRADE 在系统评价中应用的必要性及注意事项. 中国循证医学杂志, 2013, 13(12): 1401-1404.
- 31. Vernooij RWM, Alonsocoello P, Brouwers M, et al. Reporting Items for updated clinical guidelines: checklist for the reporting of updated guidelines (CheckUp). PLoS Med, 2017, 14(1): e1002207.
- 32. Hamilton BE, Martin JA, Osterman MJ, et al. Births: final data for 2014. Natl Vital Stat Rep, 2015, 64: 1.
- 33. 张亚峰, 孙桂香. 低体重儿母亲妊娠期危险因素的 Meta 分析. 中国妇幼保健, 2016, 31(5): 1115-1118.
- 34. Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet, 2011, 377(9774): 1331-1340.
- 35. Morris JK, Vigan CD, Mutton DE, et al. Risk of a Down syndrome live birth in women 45 years of age and older. Prenat Diagn, 2005, 25(4): 275-278.
- 36. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled Studies. BMJ, 2005, 330(7491): 565.
- 37. Heffner LJ. Advanced maternal age--how old is too old? N Engl J Med, 2004, 351(19): 1927-1929.
- 38. 薛静, 陈立章, 薛蕾, 等. 小儿脑性瘫痪母亲妊娠期危险因素的 Meta 分析. 中国当代儿科杂志, 2013, 15(7): 535-540.
- 39. 孙瑜, 朱依敏. 高龄不育夫妇: 现在辅助生殖技术之惑. 中国计划生育和妇产科, 2014, 6(8): 1-3.
- 40. 杨燕飞, 傅锦媚, 阮祥燕. 子宫肌瘤患病年龄分布与追踪研究. 实用妇产科杂志, 2008, 24(5): 299-301.
- 41. 乔杰, 杨蕊. 高龄辅助生殖技术临床结局. 中国实用妇科与产科杂志, 2017, 33(1): 64-67.
- 42. Timofeev J, Reddy UM, Huang CC, et al. Obstetric complications, neonatal morbidity, and indications for cesarean delivery by maternal age. Obstet Gynecol, 2013, 122(6): 1184-1195.
- 43. Pregnancy in older age increases stroke, heart attack risk years later.AHA/ASA Newsroom. 2016. Available at: http://newsroom.heart.org/news/pregnancy-in-older-age-increases-stroke-heart-attack-risk-years-later.
- 44. Committee Opinion No. 589: Female age-related fertility decline. Obstet Gynecol, 2014: 663-634.
- 45. O’Flynn N. Fertility: assessment and treatment for people with fertility problems: NICE guideline. Br J Gen Pract, 2014, 64(618): 50-51.
- 46. Reproductive Endocrinology and Infertility Committee. Advanced reproductive age and fertility. J Obstet Gynaecol Can, 2011, 33(11): 1165-1175.
- 47. 中国医师协会生殖医学专业委员会. 高龄女性不孕诊治指南. 生殖与避孕, 2017, 37(2): 87-100.
- 48. Faddy MJ, Gosden RG, Gougeon A. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod, 1992, 7(10): 1342-1346.
- 49. 刘继龙, 林春莲, 蒙钟明, 等. 年龄及性激素预测卵巢储备功能的临床研究. 基层医学论坛, 2013, 17(1): 3-4.
- 50. 2015 assisted reproductive technology fertility clinic success rates report, national center for chronic disease prevention and health promotion & division of reproductive health. Available at: https://www.cdc.gov/art/reports/2015/fertility-clinic.html.
- 51. 梁琳, 陈秀娟. 高龄不孕患者不同辅助生殖技术的胚胎发育情况及妊娠结局分析. 中华妇幼临床医学杂志 (电子版), 2014, 10(6): 770-773.
- 52. 谢雅琴, 肖红, 柳鸣, 等. 行辅助生殖技术治疗的高龄不孕女性生育二胎的心理健康相关因素分析. 生殖与避孕, 2016, 36(12): 1031-1035.
- 53. Kelly-Weeder S, Cox CL. The Impact of lifestyle risk factors on female infertility. Women Health, 2006, 44(4): 1-23.
- 54. 韩晓霞, 左瑞菊, 马肖. 窦卵泡计数、抗苗勒管激素与性激素检测评价卵巢储备的研究. 中国医药导报, 2017, 14(18): 117-120.
- 55. 陈士岭. 卵巢储备功能的评价. 国际生殖健康/计划生育杂志, 2009, 28(5): 281-286.
- 56. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril, 2015, 103(03): e9-e17.
- 57. Zhang HH, Xu PY, Wu J, et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J Ovarian Res, 2014, 7(1): 93.
- 58. 宋慧玲, 郭艺红, 孙莹璞, 等. 生长激素对不同年龄卵巢储备功能趋于低下患者 IVF-ET 治疗结局的影响. 生殖与避孕, 2013, 33(1): 58-62.
- 59. Kara M, Aydin T, Aran T, et al. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur J Obstet Gynecol Reprod Biol, 2014, 173: 63-65.
- 60. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet, 2007, 24(12): 629-634.
- 61. Smotrich DB, Widra EA, Gindoff PR, et al. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril, 1995, 64(6): 1136.
- 62. Broer SL, Broekmans FJ, Laven JS, et al. Anti-mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update, 2014, 20(5): 688-701.
- 63. Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology, 2002, 143(3): 1076-1084.
- 64. Wang LR, Wang Y, Lou Y, et al. Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril, 2015, 103(1): 119.
- 65. 杨泽星, 朱琼媛, 赵富鲜, 等. 早卵泡期血清抗苗勒管激素水平在预测卵巢低反应中的价值探讨. 实用妇产科杂志, 2016, 32(8): 32.
- 66. Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertil Steril, 2013, 99(7): 1825.
- 67. Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA, 2017, 318(14): 1367-1376.
- 68. Eldar-Geva T, Ben-Chetrit A, Spitz IM, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod, 2005, 20(11): 3178-3183.
- 69. McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod, 2007, 22(3): 778-785.
- 70. Hall JE, Welt CK, Cramer DW. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum Reprod, 1999, 14(2): 409-415.
- 71. Creus M, Penarrubia J, Fabregues F, et al. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod, 2000, 15(11): 2341-2346.
- 72. Smeenk JM, Sweep FC, Zielhuis GA, et al. Anti-mullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril, 2007, 87(1): 223-226.
- 73. Practice COG. Committee opinion no. 618: Ovarian reserve testing. Obstet Gynecol, 2015, 125(1): 268.
- 74. Kwe J, Ehing ME, Sehats R, et al. Ovarian volume and antral follicle count for the prediction of low an d hyper responders with in vitro fertilization. Reprod Biol Endco rinol, 2007, 15(5): 9-18.
- 75. Frattarelli JL, Lauria-Costab DF, Miller BT, et al. Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. Fertil Steril, 2000, 74(3): 512-517.
- 76. Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. J Gynecol Obstet Hum Reprod, 2017, 46(1): 1-7.
- 77. Ji J, Ju XQ, Wang JF, et al. Effectiveness of dehydroepiandrosterone in poor ovarian responders undergoing in vitro fertilization: a meta-analysis of randomized controlled trials. Int J Clin Exp Med, 2016, 9(11): 20835-20845.
- 78. Li J, Yuan H, Chen Y, et al. A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. Int J Gynaecol Obstet, 2015, 131(3): 240-245.
- 79. 董娟, 徐望明, 董兰, 等. IVF-ET 前使用脱氢表雄酮对卵巢储备功能低下患者妊娠结局影响的系统评估. 生殖医学杂志, 2015, 24(6): 436-443.
- 80. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med, 2009, 6(9): 2579-2590.
- 81. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst, 2005, 97(10): 755-765.
- 82. Li XL, Wang L, Lv F, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore), 2017, 96(12): e6443.
- 83. Harper K, Proctor M, Hughes E, et al. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev, 2009, (3): CD000099.
- 84. 张平, 王蕴颖. 生长激素辅助促排卵改善卵巢低反应患者不孕治疗的结局. 中国妇幼保健, 2012, 27(3): 395-396.
- 85. 孙婧, 权孝珍, 谢明霞, 等. 1382 周期宫腔内夫精人工授精临床因素分析. 中国妇幼保健, 2011, 26(11): 1658-1660.
- 86. 陈辉, 周敏, 李秋颖, 等. 影响夫精宫腔内人工授精临床妊娠率的相关因素分析. 中国优生与遗传杂志, 2012, 20(1): 98-101.
- 87. 卢伟英, 刘西茹, 黄元华, 等. 718 周期夫精宫腔内人工授精临床因素分析. 海南医学院学报, 2006, 12(4): 310-313.
- 88. 程艽, 张莉嘉, 苏慧. 男性不育相关因素对夫精人工授精妊娠率的影响. 中国优生与遗传杂志, 2011, 19(3): 99-102.
- 89. Goldman MB, Thornton KL, Ryley D, et al. A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). Fertil Steril, 2014, 101(6): 1574-1581.
- 90. Hill MJ, Levens ED, Levy G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril, 2012, 97(5): 1108-1114.
- 91. 熊芳, 周萍, 胡玲卿, 等. 重组促黄体生成素在卵巢储备正常患者超促排卵中的作用. 中国妇幼保健, 2016, 31(2): 336-338.
- 92. 杨军, 吴淑卿. 长效长方案超促排卵中晚期添加黄体生成素对体外受精-胚胎移植结局的影响. 国际医药卫生导报, 2016, 22(19): 2929-2933.
- 93. Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged≥ 35 years: a randomized controlled trial. Hum Reprod, 2015, 30(5): 1188-1195.
- 94. Mochtar MH, Veen FVD. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev, 2007, (2): CD005070.
- 95. Boulet SL, Mehta A, Kissin DM. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA, 2015, 313(3): 255-263.
- 96. Rumste MMV, Evers JL, Farquhar C. Intra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in couples with non-male subfertility. Cochrane Database Syst Rev, 2003, (2): CD001301.
- 97. Wen J, Jie J, Ding C, et al. Birth defects in children conceived by invitro fertilization and intracytoplasmic sperm injection: a meta-analysis. Fertil Steril, 2012, 97(6): 1331-1337.
- 98. National Institute for Health and Care Excellence. Fertility problems assessment and treatment. 2013.
- 99. Abramowicz J S, Kossoff G, Maršál K, et al. International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). Ultrasound Obstet Gynecol, 2000, 16(6): 594-596.
- 100. Harton G, Braude P, Lashwood A, et al. ESHRE PGD consortium best practice guidelines for organization of a PGD centre for PGD/preimplantation genetic screening. Hum Reprod, 2010, 26(1): 14-24.
- 101. Okun N, Sierra S, Wilson RD, et al. Pregnancy outcomes after assisted human reproduction. J Obstet Gynaecol Can, 2014, 36(1): 64-83.
- 102. Staessen C, Platteau P, Van AE, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. Hum Reprod, 2004, 19(12): 2849-2858.
- 103. Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med, 2007, 357(17): 1770.
- 104. Platteau P, Staessen C, An M, et al. Preimplantation genetic diagnosis for aneuploidy screening in patients with unexplained recurrent miscarriages. Fertil Steril, 2005, 83(2): 393-397.
- 105. Blockeel C, Schutyser V, De Vos A, et al. Prospectively randomized controlled trial of PGS in IVF/ICSI patients with poor implantation. Reprod Biomed Online, 2008, 17(6): 848-854.
- 106. Mastenbroek S, Twisk M, Van der Veen F, et al. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. Hum Reprod Update, 2011, 19(2): 454-466.
- 107. Chen M, Wei S, Hu J, et al. Can comprehensive chromosome screening technology improve IVF/ICSI outcomes? A meta-analysis. PLoS One, 2015, 10(10): e0140779.
- 108. Yang Z, Lin J, Zhang J, et al. Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study. BMC Med Genomics, 2015, 8(1): 30.
- 109. Lai HH, Chuang TH, Wong LK, et al. Identification of mosaic and segmental aneuploidies by next-generation sequencing in preimplantation genetic screening can improve clinical outcomes compared to array-comparative genomic hybridization. Mol Cytogenet, 2017, 10(1): 14.
- 110. 徐艳文, 黄国宁, 孙海翔, 等. 高通量基因测序植入前胚胎遗传学诊断和筛查技术规范 (试行). 生殖医学杂志, 2017, 26(5): 391-398.
- 111. 黄锦, 马彩虹. 植入前胚胎遗传学诊断及筛查技术与规范. 中国实用妇科与产科杂志, 2015, 31(9): 814-817.
- 112. 孙莹璞, 李刚. PGD/PGS 的安全性. 2014 浙江省计划生育与生殖医学学术年会暨“生殖安全转化医学研讨会”, 2014.
- 113. Pandian Z, Marjoribanks J, Ozturk O, et al. Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection. Cochrane Database Syst Rev, 2013, (7): CD003416.
- 114. McLernon DJ, Harrild K, Bergh C, et al. Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials. BMJ, 2010, 341: c6945.
- 115. Kissin DM, Kulkarni AD, Kushnir VA, et al. Number of embryos transferred after in vitro fertilization and good perinatal outcome. Obstet Gynecol, 2014, 123(2 Pt 1): 239-247.
- 116. Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril, 2017, 107(4): 901-903.
- 117. NICE. Fertility problems: assessment and treatment (CG156). 2016. Available at: https://www.nice.org.uk/guidance/cg156/resources/.
- 118. Lawlor DA, Nelson SM. Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. Lancet, 2012, 379(9815): 521-527.
- 119. Fiddelers AA, Severens JL, Dirksen CD, et al. Economic evaluations of single- versus double-embryo transfer in IVF. Hum Reprod Update, 2007, 13(1): 5-13.
- 120. Scotland GS, McLernon D, Kurinczuk JJ, et al. Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon. BJOG, 2011, 118(9): 1073-1083.
- 121. Kjellberg AT, Carlsson P, Bergh C. Randomized single versus double embryo transfer: obstetric and paediatric outcome and a cost-effectiveness analysis. Hum Reprod, 2006, 21(1): 210-216.
- 122. Joint Society of Obstetricians and Gynaecologist of Canada–Canadian Fertility and Andrology Society Clinical Practice Guidelines Committee. Elective Single Embryo Transfer Following in vitro Fertilization. J Obstet Gynaecol Can, 2010, 32(4): 363-377.
- 123. Gardner DK, Surrey E, Minjarez D, et al. Single blastocyst transfer: a prospective randomized trial. Fertil Steril, 2004, 81(3): 551-555.
- 124. The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology. Criteria for number of embryos to transfer: a committee opinion. Fertil Steril, 2013, 99(1): 44-46.
- 125. 薛亚梅, 童晓嵋, 张松英. 黄体酮肌肉注射与阴道缓释凝胶对 IVF-ET 结局影响的 Meta 分析. 生殖与避孕, 2015, 35(4): 252-258.
- 126. Zargar M, Saadati N, Ejtahed MS. Comparison the effectiveness of oral dydrogesterone, vaginal progesterone suppository and progesterone ampule for luteal phase support on pregnancy rate during ART cycles. Int J Pharm Res Allied Sci, 2016, 5(3): 229-236.
- 127. Saharkhiz N, Zamaniyan M, Salehpour S, et al. A comparative study of dydrogesterone and micronized Progesterone for luteal Phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol, 2016, 32(3): 213-217.
- 128. 魏臻, 孙骏. 黄体酮注射液事件引起的安全用药思考. 中国药房, 2016, 27(13): 1749-1751.
- 129. 张红英. 黄体酮肌内注射的局部不良反应与护理措施. 中国医药指南, 2012, 10(21): 672-673.
- 130. 中华人民共和国卫生部. 人类辅助生殖技术规范. 中国生育健康杂志, 2004, 15(1): 4-9.
- 131. Dodd JM, Dowswell T, Crowther CA. Reduction of the number of fetuses for women with a multiple pregnancy. Cochrane Database Syst Rev, 2015, (11): CD003932.
- 132. 王蕴颖, 赵静, 张平, 等. 体型瘦小女性经辅助生殖获双胎妊娠后减胎与否对妊娠结局的影响. 中国妇幼保健, 2013, 28(26): 4343-4344.
- 133. Gupta S, Fox N S, Feinberg J, et al. Outcomes in twin pregnancies reduced to singleton pregnancies compared with ongoing twin pregnancies. Am J Obstet Gynecol, 2015, 213(4): 580.
- 134. 潘云冬. 辅助生殖技术后多胎妊娠减灭术对妊娠结局及子代的影响. 杭州: 浙江大学, 2015.
- 135. 赵霞. 123 例多胎妊娠行选择性减胎患者妊娠结局临床因素分析. 武汉: 华中科技大学, 2011.
- 136. 刘艳, 王谢桐, 李红燕, 等. 多胎妊娠选择性减胎术的时机对妊娠结局的影响. 中华围产医学杂志, 2012, 15(10): 605-609.
- 137. Haas J, Barzilay E, Hourvitz A, et al. Outcome of early versus late multi-fetal pregnancy reduction. Reprod Biomed Online, 2016, 33(5): 629-634.
- 138. 朱小凤. 减胎时机与妊娠结局的关系研究. 中国实用医药, 2009, 4(30): 201-202.
- 139. Seoud MA, Toner JP, Kruithoff C, et al. Outcome of twin, triplet, and quadruplet in vitro fertilization pregnancies: the Norfolk experience. Fertil Steril, 1992, 57(4): 825.
- 140. Stevenson R C, Mccabe C J, Pharoah P O, et al. Cost of care for a geographically determined population of low birthweight infants to age 8-9 years. II. Arch Dis Child Fetal Neonatal Ed, 1996, 74(2): F118.
- 141. 刘泽星, 薛薇, 邓燕, 等. 阴道给药与肌内注射黄体酮对子宫内膜孕激素水平影响的研究. 实用妇产科杂志, 2017, 33(3): 220-222.
- 142. 赵敏, 郑文捷, 李晓东, 等. 黄体酮注射液与阴道缓释凝胶对实施体外受精与胚胎移植技术孕妇妊娠结局的影响比较: Meta 分析. 福建医科大学学报, 2017, 51(1): 61-67.
- 143. 连海丽. 口服地屈孕酮在黄体功能不全所致先兆流产保胎中的优势临床观察. 中国现代药物应用, 2016, 10(16): 219-220.
- 144. 胡晓东, 彭月婷, 曾勇, 等. 阴道黄体酮栓剂黄体支持是否更具优点? 生殖医学杂志, 2010, 19(3): 196-199.